New CEO For Sun BioPharma
This article was originally published in Scrip
Sun BioPharma Inc., which is developing therapies for the treatment of pancreatic cancer, has appointed David Kaysen president and chief executive officer as well as a member of its board of directors. Kaysen's previous roles include president and chief executive officer of Uroplasty, a publicly traded global medical device company now part of Cogentix Medical.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.